Table 1.
Characteristics of included studies.
| The first author (years) | Total cases (E/C) | Sex, M/F | Age (y), range (mean) | Course of disease (y) range (mean) | NYHA | Duration | Intervention measures | Outcome indicators |
|---|---|---|---|---|---|---|---|---|
| Chen (2017) | 152 (76/76) | C: 40/36 | C: 44–81 (57.75 ± 7.52) | NR | C: II20, III31, IV25 | 4 W | C: CT 25 mg/time, 2 times/d | ①②③⑧ |
| E: 42/34 | E: 47–84 (56.64 ± 7.32) | E: II18, III30, IV28 | E: C + 0.5 gQ/time, 3 times/d | ⑨ | ||||
|
| ||||||||
| Hu (2019) | 82 (41/41) | C: 29/12 | C: 42–70 (59.89 ± 6.02) | NR | NR | 2 M | C: CT 7 mg/time, 2 times/d | ①②③④ |
| E: 26/15 | E: 47–84 (60.34 ± 7.21) | E: C + 0.5 gQ/time, 3 times/d | ⑨ | |||||
|
| ||||||||
| Jiang (2019) | 84 (42/42) | C: 20/22 | C: 50–75 (56.55 ± 5.95) | NR | C: I-II17, III20, IV5 | 3 M | C: CT 50 mg/time, 2 times/d | ①④⑥⑧ |
| E: 25/17 | E: 50–75 (57.43 ± 6.45) | E: I-II16, III18, IV8 | E: C + 0.7 gQ/time, 3 times/d | — | ||||
|
| ||||||||
| Jin (2019) | 85 (45/40) | C: 25/15 | C: 44–75 (58.72 ± 5.22) | NR | III57, IV28 | 2 M | C: CT 20 mg/time, 3 times/d | ①②③④ |
| E: 25/20 | E: 45–72 (57.46 ± 5.15) | E: C + 0.5 gQ/time, 3 times/d | ⑤⑦⑨ | |||||
|
| ||||||||
| Li (2017) | 94 (47/47) | C: 27/20 | C: 59.14 ± 4.97 | C: 5.53 ± 0.74 | C: III32, IV15 | 8 W | C: CT 20 mg/time, 3 times/d | ①②③④ |
| E: 29/18 | E: 58.36 ± 5.39 | E: 5.41 ± 0.83 | E: III31, IV16 | E: C + 0.5 gQ/time, 3 times/d | ⑤⑨ | |||
|
| ||||||||
| Li (2018) | 210 (105/105) | C: 57/48 | C: 50–70 (62.35 ± 6.86) | C: 2–5 (2.31 ± 0.37) | C: II32, III47, IV26 | 3 M | C: CT 20 mg/time, 3 times/d | ①②③④ |
| E: 63/42 | E: 52–68 (62.44 ± 6.73) | E: 2–5 (2.29 ± 0.41) | E: II34, III46, IV25 | E: C + 0.5 gQ/time, 3 times/d | ⑤ | |||
|
| ||||||||
| Liu (2019) | 178 (79/79) | 98/80 | 55–78 (64.52 ± 6.67) | NR | NR | 1 W | C: CT 12.5 mg/time, 3 times/d | ①②③④ |
| E: C + 0.5 gQ/time, 3 times/d | ⑥⑨ | |||||||
|
| ||||||||
| Wu (2016) | 160 (80/80) | C: 38/42 | C: 50–85 (63.4 ± 9.4) | C: 4–21 (10.6 ± 4.9) | C: III61, IV19 | 8 W | C: CT | ①④⑤⑦ |
| E: 36/44 | E: 52–86 (63.2 ± 13.6) | E: 3–22 (10.1 ± 5.1) | E: III64, IV16 | E: C + 0.5 gQ/time, 3 times/d | ⑧⑨ | |||
|
| ||||||||
| Xin (2015) | 80 (40/40) | NR | NR | NR | NR | 8 W | C: CT | ①⑥⑦⑨ |
| E: C + 0.5 gQ/time, 3 times/d | — | |||||||
|
| ||||||||
| Xu (2017) | 146 (76/70) | C: 38/32 | C: 52–84 (63.8 ± 12.2) | C: 3–18 (10.1 ± 5.2) | C: III37, IV33 | 8 W | C: CT | ①④⑤⑦ |
| E: 42/34 | E: 53–82 (62.4 ± 11.8) | E: 2–17 (9.5 ± 4.3) | E: III40, IV36 | E: C + 0.5 gQ/time, 3 times/d | ⑨ | |||
|
| ||||||||
| Xu (2019) | 30 (15/15) | C: 9/6 | C: 54–79 (64.27 ± 3.41) | C: 2–18 (10.36 ± 5.27) | C: III14, IV1 | 1 M | C: CT 20 mg/time, 1 time/d | ①④⑤⑦ |
| E: 7/8 | E: 53–78 (64.19 ± 3.46) | E: 2–17 (10.26 ± 5.37) | E: III13, IV2 | E: C + 0.5 gQ/time, 2 times/d | ⑧ | |||
|
| ||||||||
| Zeng (2019) | 98 (49/49) | NR | C: 74.92 ± 11.08 | NR | NR | 3 M | C: CT 2.5–20 mg/time, 3 times/d | ①②③④ |
| E: 72.47 ± 9.89 | E: C + 0.5 gQ/time, 3 times/d | ⑥⑨ | ||||||
|
| ||||||||
| Zhang (2017) | 96 (48/48) | C: 29/19 | C: 51–74 (61.34 ± 2.84) | C: 2–13 (7.18 ± 1.36) | C: III31, IV17 | 3 M | C: CT 20 mg/time, 3 times/d | ①②③④ |
| E: 26/22 | E: 50–73 (64.19 ± 3.46) | E: 2–12 (7.23 ± 1.32) | E: III29, IV19 | E: C + 0.5 gQ/time, 3 times/d | ⑤⑦⑧⑨ | |||
|
| ||||||||
| Zhang (2017) | 86 (44/42) | C: 21/21 | C: 62.1 ± 9.1 | C: 3.7 ± 3.1 | C: II23, III12, IV7 | 3 M | C: CT 20 mg/time, 3 times/d | ④⑦ |
| E: 19/25 | E: 57.8 ± 6.7 | E: 4.6 ± 2.7 | E: II19, III17, IV8 | E: C + 0.5 gQ/time, 3 times/d | — | |||
|
| ||||||||
| Zhang (2018) | 80 (40/40) | C: 25/15 | C: 47–75 (55.17 ± 5.62) | C: 1–8 (5.87 ± 0.76) | C: III26, IV14 | 8 W | C: CT 20 mg/time, 3 times/d | ①②③④ |
| E: 23/17 | E: 45–73 (54.32 ± 5.26) | E: 2–9 (5.61 ± 0.83) | E: III27, IV13 | E: C + 0.5 gQ/time, 3 times/d | — | |||
|
| ||||||||
| Zhao (2017) | 90 (45/45) | C: 22/23 | C: 65.23 ± 10.64 | C: 6.57 ± 3.37 | C: II16, III18, IV11 | 3 M | C: CT 20 mg/time, 3 times/d | ①②③④ |
| E: 20/25 | E: 64.07 ± 11.37 | E: 7.05 ± 4.23 | E: II13, III20, IV12 | E: C + 0.5 gQ/time, 3 times/d | ⑤⑧⑨ | |||
|
| ||||||||
| Zou (2019) | 76 (38/38) | C: 20/18 | C: 46–75 (61.52 ± 5.81) | C: 1–6 (2.99 ± 0.83) | C: I8, II8, III11, IV11 | 4 W | C: CT 20 mg/time, 1 time/d | ①②③④ |
| E: 21/17 | E: 46–75 (61.38 ± 5.71) | E: 1–6 (2.915 ± 0.76) | E: I9, II7, III9, IV13 | E: C + 0.5 gQ/time, 3 times/d | ⑤⑧⑨ | |||
|
| ||||||||
| Ye (2020) | 64 (32/32) | C: 21/11 | C: 58–76 (63.7 ± 14.1) | C: 3–8 (5.0 ± 2.1) | C: I-II20, III12 | 3 M | C: CT 50 mg/time, 2 times/d | ①⑥⑧⑨ |
| E: 20/12 | E: 51–78 (64.5 ± 15.3) | E: 3–8 (5.5 ± 1.8) | E: I-II22, III10 | E: C + 0.52 gQ/time, 3 times/d | — | |||
|
| ||||||||
| An (2020) | 90 (45/45) | C: 29/16 | C: 53–74 (57.85 ± 3.73) | NR | NR | 8 W | C: CT 10 mg/time, 2 times/d | ①④⑥⑧ |
| E: 33/12 | E: 54–72 (58.12 ± 2.25) | E: C + 0.5 gQ/time, 3 times/d | — | |||||
|
| ||||||||
| Li (2020) | 98 (49/49) | C: 28/21 | C: 51–76 (63 ± 6) | NR | NR | 12 W | C: CT 10 mg/time, 2 times/d | ①⑥ |
| E: 26/23 | E: 49–79 (63 ± 6) | E: C + 0.5 gQ/time, 3 times/d | — | |||||
|
| ||||||||
| Zhang (2020) | 83 (42/41) | C: 24/17 | C: 62.42 ± 8.60 | NR | C: II23, III14, IV4 | 3 M | C: CT | ①④⑤⑨ |
| E: 27/15 | E: 65.07 ± 8.42 | E: II20, III16, IV6 | E: C + 0.5 gQ/time, 3 times/d | — | ||||
Notes: C, control group; E, experimental group; F, female; M, male; NR, not report; NYHA, New York Heart Association; CT, conventional treatment; Q, Qishen Yiqi dropping pill; W, weeks; M, months. Outcome indicators (① clinical efficacy rate; ②LVESD; ③LVEDD; ④LVEF; ⑤BNP; ⑥NT-proBNP; ⑦6-MWD; ⑧other indicators; ⑨adverse reactions).